The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Liposomal and Lipid-based Nanoparticle Drug Market Research Report 2025

Global Liposomal and Lipid-based Nanoparticle Drug Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1987751

No of Pages : 102

Ask Your Query
Synopsis
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
The global Liposomal and Lipid-based Nanoparticle Drug market was valued at US$ 5019 million in 2023 and is anticipated to reach US$ 9855.2 million by 2030, witnessing a CAGR of 10.0% during the forecast period 2024-2030.
The liposomes nanoparticle drugs market is driven by the increasing demand for targeted drug delivery systems and the potential of liposomes to improve therapeutic efficacy. Liposomes are nanoscale vesicles composed of lipid bilayers that can encapsulate various drugs and deliver them to specific target sites in the body. This targeted drug delivery offers benefits such as reduced side effects, improved drug bioavailability, and enhanced therapeutic outcomes. As the prevalence of chronic diseases rises and the need for personalized medicine grows, liposomes nanoparticle drugs gain popularity in the pharmaceutical industry. Moreover, advancements in nanotechnology and biopharmaceutical research have led to the development of innovative liposomal formulations for a wide range of diseases. However, the market also faces challenges, including the high costs associated with liposomal drug development and production. Additionally, regulatory complexities related to nanomedicines and the need for comprehensive safety evaluations pose obstacles to market growth. To leverage the market's potential fully, manufacturers need to focus on cost-effectiveness, quality assurance, and robust clinical data to gain regulatory approvals and establish the efficacy and safety of liposomes nanoparticle drugs.
This report aims to provide a comprehensive presentation of the global market for Liposomal and Lipid-based Nanoparticle Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposomal and Lipid-based Nanoparticle Drug.
Report Scope
The Liposomal and Lipid-based Nanoparticle Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Liposomal and Lipid-based Nanoparticle Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Liposomal and Lipid-based Nanoparticle Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences
Segment by Type
Liposomes Drugs
Lipid Nanoparticle Drugs
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Liposomal and Lipid-based Nanoparticle Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Liposomes Drugs
1.2.3 Lipid Nanoparticle Drugs
1.3 Market by Application
1.3.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Perspective (2019-2030)
2.2 Liposomal and Lipid-based Nanoparticle Drug Growth Trends by Region
2.2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Region (2019-2024)
2.2.3 Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Region (2025-2030)
2.3 Liposomal and Lipid-based Nanoparticle Drug Market Dynamics
2.3.1 Liposomal and Lipid-based Nanoparticle Drug Industry Trends
2.3.2 Liposomal and Lipid-based Nanoparticle Drug Market Drivers
2.3.3 Liposomal and Lipid-based Nanoparticle Drug Market Challenges
2.3.4 Liposomal and Lipid-based Nanoparticle Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Revenue
3.1.1 Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Revenue (2019-2024)
3.1.2 Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Players (2019-2024)
3.2 Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Liposomal and Lipid-based Nanoparticle Drug Revenue
3.4 Global Liposomal and Lipid-based Nanoparticle Drug Market Concentration Ratio
3.4.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Liposomal and Lipid-based Nanoparticle Drug Revenue in 2023
3.5 Liposomal and Lipid-based Nanoparticle Drug Key Players Head office and Area Served
3.6 Key Players Liposomal and Lipid-based Nanoparticle Drug Product Solution and Service
3.7 Date of Enter into Liposomal and Lipid-based Nanoparticle Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Liposomal and Lipid-based Nanoparticle Drug Breakdown Data by Type
4.1 Global Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Type (2019-2024)
4.2 Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Type (2025-2030)
5 Liposomal and Lipid-based Nanoparticle Drug Breakdown Data by Application
5.1 Global Liposomal and Lipid-based Nanoparticle Drug Historic Market Size by Application (2019-2024)
5.2 Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Liposomal and Lipid-based Nanoparticle Drug Market Size (2019-2030)
6.2 North America Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2019-2024)
6.4 North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size (2019-2030)
7.2 Europe Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2019-2024)
7.4 Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size (2019-2030)
8.2 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size (2019-2030)
9.2 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2019-2024)
9.4 Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size (2019-2030)
10.2 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Detail
11.1.2 Johnson & Johnson Business Overview
11.1.3 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Introduction
11.1.4 Johnson & Johnson Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.1.5 Johnson & Johnson Recent Development
11.2 Sun Pharmaceutical
11.2.1 Sun Pharmaceutical Company Detail
11.2.2 Sun Pharmaceutical Business Overview
11.2.3 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Introduction
11.2.4 Sun Pharmaceutical Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.2.5 Sun Pharmaceutical Recent Development
11.3 CSPC
11.3.1 CSPC Company Detail
11.3.2 CSPC Business Overview
11.3.3 CSPC Liposomal and Lipid-based Nanoparticle Drug Introduction
11.3.4 CSPC Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.3.5 CSPC Recent Development
11.4 Kinyond
11.4.1 Kinyond Company Detail
11.4.2 Kinyond Business Overview
11.4.3 Kinyond Liposomal and Lipid-based Nanoparticle Drug Introduction
11.4.4 Kinyond Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.4.5 Kinyond Recent Development
11.5 Teva
11.5.1 Teva Company Detail
11.5.2 Teva Business Overview
11.5.3 Teva Liposomal and Lipid-based Nanoparticle Drug Introduction
11.5.4 Teva Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.5.5 Teva Recent Development
11.6 Fudan-Zhangjiang
11.6.1 Fudan-Zhangjiang Company Detail
11.6.2 Fudan-Zhangjiang Business Overview
11.6.3 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Introduction
11.6.4 Fudan-Zhangjiang Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.6.5 Fudan-Zhangjiang Recent Development
11.7 Zydus Cadila
11.7.1 Zydus Cadila Company Detail
11.7.2 Zydus Cadila Business Overview
11.7.3 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Introduction
11.7.4 Zydus Cadila Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.7.5 Zydus Cadila Recent Development
11.8 TTY Biopharma
11.8.1 TTY Biopharma Company Detail
11.8.2 TTY Biopharma Business Overview
11.8.3 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Introduction
11.8.4 TTY Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.8.5 TTY Biopharma Recent Development
11.9 Pacira
11.9.1 Pacira Company Detail
11.9.2 Pacira Business Overview
11.9.3 Pacira Liposomal and Lipid-based Nanoparticle Drug Introduction
11.9.4 Pacira Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.9.5 Pacira Recent Development
11.10 Luye Pharma
11.10.1 Luye Pharma Company Detail
11.10.2 Luye Pharma Business Overview
11.10.3 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Introduction
11.10.4 Luye Pharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.10.5 Luye Pharma Recent Development
11.11 Leadiant Biosciences
11.11.1 Leadiant Biosciences Company Detail
11.11.2 Leadiant Biosciences Business Overview
11.11.3 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Introduction
11.11.4 Leadiant Biosciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.11.5 Leadiant Biosciences Recent Development
11.12 Ipsen
11.12.1 Ipsen Company Detail
11.12.2 Ipsen Business Overview
11.12.3 Ipsen Liposomal and Lipid-based Nanoparticle Drug Introduction
11.12.4 Ipsen Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.12.5 Ipsen Recent Development
11.13 Sayre Therapeutics
11.13.1 Sayre Therapeutics Company Detail
11.13.2 Sayre Therapeutics Business Overview
11.13.3 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Introduction
11.13.4 Sayre Therapeutics Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.13.5 Sayre Therapeutics Recent Development
11.14 Jazz
11.14.1 Jazz Company Detail
11.14.2 Jazz Business Overview
11.14.3 Jazz Liposomal and Lipid-based Nanoparticle Drug Introduction
11.14.4 Jazz Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.14.5 Jazz Recent Development
11.15 Alnylam
11.15.1 Alnylam Company Detail
11.15.2 Alnylam Business Overview
11.15.3 Alnylam Liposomal and Lipid-based Nanoparticle Drug Introduction
11.15.4 Alnylam Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.15.5 Alnylam Recent Development
11.16 Bausch Health
11.16.1 Bausch Health Company Detail
11.16.2 Bausch Health Business Overview
11.16.3 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Introduction
11.16.4 Bausch Health Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.16.5 Bausch Health Recent Development
11.17 Acrotech Biopharma
11.17.1 Acrotech Biopharma Company Detail
11.17.2 Acrotech Biopharma Business Overview
11.17.3 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Introduction
11.17.4 Acrotech Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.17.5 Acrotech Biopharma Recent Development
11.18 Takeda
11.18.1 Takeda Company Detail
11.18.2 Takeda Business Overview
11.18.3 Takeda Liposomal and Lipid-based Nanoparticle Drug Introduction
11.18.4 Takeda Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.18.5 Takeda Recent Development
11.19 Chiesi Farmaceutici
11.19.1 Chiesi Farmaceutici Company Detail
11.19.2 Chiesi Farmaceutici Business Overview
11.19.3 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Introduction
11.19.4 Chiesi Farmaceutici Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.19.5 Chiesi Farmaceutici Recent Development
11.20 Gilead Sciences
11.20.1 Gilead Sciences Company Detail
11.20.2 Gilead Sciences Business Overview
11.20.3 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Introduction
11.20.4 Gilead Sciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
11.20.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Liposomes Drugs
Table 3. Key Players of Lipid Nanoparticle Drugs
Table 4. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Region (2019-2024)
Table 8. Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Region (2025-2030)
Table 10. Liposomal and Lipid-based Nanoparticle Drug Market Trends
Table 11. Liposomal and Lipid-based Nanoparticle Drug Market Drivers
Table 12. Liposomal and Lipid-based Nanoparticle Drug Market Challenges
Table 13. Liposomal and Lipid-based Nanoparticle Drug Market Restraints
Table 14. Global Liposomal and Lipid-based Nanoparticle Drug Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Players (2019-2024)
Table 16. Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposomal and Lipid-based Nanoparticle Drug as of 2023)
Table 17. Ranking of Global Top Liposomal and Lipid-based Nanoparticle Drug Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Liposomal and Lipid-based Nanoparticle Drug Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Liposomal and Lipid-based Nanoparticle Drug Product Solution and Service
Table 21. Date of Enter into Liposomal and Lipid-based Nanoparticle Drug Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Type (2019-2024)
Table 25. Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Type (2025-2030)
Table 27. Global Liposomal and Lipid-based Nanoparticle Drug Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Application (2019-2024)
Table 29. Global Liposomal and Lipid-based Nanoparticle Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share by Application (2025-2030)
Table 31. North America Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size by Country (2025-2030) & (US$ Million)
Table 46. Johnson & Johnson Company Detail
Table 47. Johnson & Johnson Business Overview
Table 48. Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Product
Table 49. Johnson & Johnson Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 50. Johnson & Johnson Recent Development
Table 51. Sun Pharmaceutical Company Detail
Table 52. Sun Pharmaceutical Business Overview
Table 53. Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Product
Table 54. Sun Pharmaceutical Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 55. Sun Pharmaceutical Recent Development
Table 56. CSPC Company Detail
Table 57. CSPC Business Overview
Table 58. CSPC Liposomal and Lipid-based Nanoparticle Drug Product
Table 59. CSPC Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 60. CSPC Recent Development
Table 61. Kinyond Company Detail
Table 62. Kinyond Business Overview
Table 63. Kinyond Liposomal and Lipid-based Nanoparticle Drug Product
Table 64. Kinyond Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 65. Kinyond Recent Development
Table 66. Teva Company Detail
Table 67. Teva Business Overview
Table 68. Teva Liposomal and Lipid-based Nanoparticle Drug Product
Table 69. Teva Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 70. Teva Recent Development
Table 71. Fudan-Zhangjiang Company Detail
Table 72. Fudan-Zhangjiang Business Overview
Table 73. Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Product
Table 74. Fudan-Zhangjiang Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 75. Fudan-Zhangjiang Recent Development
Table 76. Zydus Cadila Company Detail
Table 77. Zydus Cadila Business Overview
Table 78. Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Product
Table 79. Zydus Cadila Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 80. Zydus Cadila Recent Development
Table 81. TTY Biopharma Company Detail
Table 82. TTY Biopharma Business Overview
Table 83. TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Product
Table 84. TTY Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 85. TTY Biopharma Recent Development
Table 86. Pacira Company Detail
Table 87. Pacira Business Overview
Table 88. Pacira Liposomal and Lipid-based Nanoparticle Drug Product
Table 89. Pacira Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 90. Pacira Recent Development
Table 91. Luye Pharma Company Detail
Table 92. Luye Pharma Business Overview
Table 93. Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Product
Table 94. Luye Pharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 95. Luye Pharma Recent Development
Table 96. Leadiant Biosciences Company Detail
Table 97. Leadiant Biosciences Business Overview
Table 98. Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Product
Table 99. Leadiant Biosciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 100. Leadiant Biosciences Recent Development
Table 101. Ipsen Company Detail
Table 102. Ipsen Business Overview
Table 103. Ipsen Liposomal and Lipid-based Nanoparticle Drug Product
Table 104. Ipsen Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 105. Ipsen Recent Development
Table 106. Sayre Therapeutics Company Detail
Table 107. Sayre Therapeutics Business Overview
Table 108. Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Product
Table 109. Sayre Therapeutics Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 110. Sayre Therapeutics Recent Development
Table 111. Jazz Company Detail
Table 112. Jazz Business Overview
Table 113. Jazz Liposomal and Lipid-based Nanoparticle Drug Product
Table 114. Jazz Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 115. Jazz Recent Development
Table 116. Alnylam Company Detail
Table 117. Alnylam Business Overview
Table 118. Alnylam Liposomal and Lipid-based Nanoparticle Drug Product
Table 119. Alnylam Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 120. Alnylam Recent Development
Table 121. Bausch Health Company Detail
Table 122. Bausch Health Business Overview
Table 123. Bausch Health Liposomal and Lipid-based Nanoparticle Drug Product
Table 124. Bausch Health Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 125. Bausch Health Recent Development
Table 126. Acrotech Biopharma Company Detail
Table 127. Acrotech Biopharma Business Overview
Table 128. Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Product
Table 129. Acrotech Biopharma Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 130. Acrotech Biopharma Recent Development
Table 131. Takeda Company Detail
Table 132. Takeda Business Overview
Table 133. Takeda Liposomal and Lipid-based Nanoparticle Drug Product
Table 134. Takeda Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 135. Takeda Recent Development
Table 136. Chiesi Farmaceutici Company Detail
Table 137. Chiesi Farmaceutici Business Overview
Table 138. Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Product
Table 139. Chiesi Farmaceutici Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 140. Chiesi Farmaceutici Recent Development
Table 141. Gilead Sciences Company Detail
Table 142. Gilead Sciences Business Overview
Table 143. Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Product
Table 144. Gilead Sciences Revenue in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024) & (US$ Million)
Table 145. Gilead Sciences Recent Development
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Type: 2023 VS 2030
Figure 3. Liposomes Drugs Features
Figure 4. Lipid Nanoparticle Drugs Features
Figure 5. Global Liposomal and Lipid-based Nanoparticle Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Application: 2023 VS 2030
Figure 7. Hospital Case Studies
Figure 8. Retail Pharmacy Case Studies
Figure 9. Other Case Studies
Figure 10. Liposomal and Lipid-based Nanoparticle Drug Report Years Considered
Figure 11. Global Liposomal and Lipid-based Nanoparticle Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Liposomal and Lipid-based Nanoparticle Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Region: 2023 VS 2030
Figure 14. Global Liposomal and Lipid-based Nanoparticle Drug Market Share by Players in 2023
Figure 15. Global Top Liposomal and Lipid-based Nanoparticle Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposomal and Lipid-based Nanoparticle Drug as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Liposomal and Lipid-based Nanoparticle Drug Revenue in 2023
Figure 17. North America Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2019-2030)
Figure 19. United States Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2019-2030)
Figure 23. Germany Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Liposomal and Lipid-based Nanoparticle Drug Market Share by Region (2019-2030)
Figure 31. China Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2019-2030)
Figure 39. Mexico Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Market Share by Country (2019-2030)
Figure 43. Turkey Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Liposomal and Lipid-based Nanoparticle Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Johnson & Johnson Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 46. Sun Pharmaceutical Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 47. CSPC Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 48. Kinyond Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 49. Teva Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 50. Fudan-Zhangjiang Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 51. Zydus Cadila Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 52. TTY Biopharma Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 53. Pacira Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 54. Luye Pharma Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 55. Leadiant Biosciences Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 56. Ipsen Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 57. Sayre Therapeutics Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 58. Jazz Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 59. Alnylam Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 60. Bausch Health Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 61. Acrotech Biopharma Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 62. Takeda Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 63. Chiesi Farmaceutici Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 64. Gilead Sciences Revenue Growth Rate in Liposomal and Lipid-based Nanoparticle Drug Business (2019-2024)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock